Glass: double digit growth in pharma

In 2014 Stevanato Group (glass pharmaceutical packaging and machinery for processing and controlling glass tubes) has reported revenues of 285 million euros, up 18.7% on the previous year.

Its EBITDA has also improved, which stands at 73 million euro, corresponding to 25.6% of revenues), while EBIT was at  49.2 million (17.3% of turnover), up compared to 38.7 million euros in the previous year (+ 27.1%).
Last year was marked by the good performance in the two business areas in which the Piombino Dese based company operates (Pharmaceutical Systems and Engineering Systems), and this in all the main markets. Its most dynamic markets are located in North, Central and South America (where, among other things, Stevanato is building a new plant in Brazil), but also in Asia Pacific, where last June the Veneto based group opened its Chinese site.

The double-digit growth of Stevanato Group has been going on for several years, driven by the positive trend of injectable drugs, and the management expects to maintain this pace in the future. Regarding the  Engineering Systems segment, the excellent year-end results are due to the performance of the company Spami, that specializes in the design and assembly of automatic lines for producing containers for pharmaceutical use, and the successful integration of InnoScan (inspection systems).

Lo sviluppo a due cifre di Stevanato Group prosegue da diversi anni, trainato dal trend positivo dei farmaci iniettabili e il management prevede di mantenere questo ritmo anche nel futuro. Per quanto riguarda il segmento Engineering Systems, gli ottimi risultati di fine esercizio si devono alle performance della società Spami, che si occupa di progettazione e assemblaggio di linee automatiche per la produzione di contenitori a uso farmaceutico, e al completamento dell’integrazione di InnoScan (sistemi di ispezione).